Executive Summary

In January 2026, MARA issued nine initial reimbursement risk assessments across cardiology, infectious disease, neurology, oncology, obesity, and immunology. The monthly profile was concentrated in the middle of the scale: two assets were assigned A (Strong), five were assigned B++ (Marginal), and two were assigned B+ (Very Weak).

The distribution matters. The January cohort contained multiple assets with credible clinical promise, but most had not yet converted that promise into payer-grade reimbursement support. In practical terms, clinical signal was often ahead of health-related quality of life evidence, comparator positioning, or cost-effectiveness maturity.

The result is a familiar pattern in early surveillance: encouraging science does not automatically translate into a strong reimbursement signal.

Trigger and Structural Context

These January actions reflect initial MARA determinations for assets entering the framework during the month. The purpose of publication is procedural. Each action records how the available evidence maps to reimbursement probability under HTA-aligned scrutiny, rather than offering a promotional summary of product potential.

Across the January set, the main structural feature was asymmetry between efficacy evidence and reimbursement readiness. Several assets showed meaningful early clinical performance, particularly in high-unmet-need settings. However, the available evidence base frequently remained incomplete in areas that matter directly to payer decision-making: validated quality-of-life data, comparator relevance, and defensible economic modeling.

This is where reimbursement risk is often under-weighted. Internal asset narratives tend to emphasize clinical novelty. HTA systems typically ask a different question: how robustly does the evidence support value versus relevant alternatives, at a price the system can defend?

Domain-Level Drivers

Clinical Effectiveness was the main source of support in January. Tecvayli and Abelacimab reached A overall because their evidence packages were more balanced, with stronger alignment between clinical effect and likely payer interpretation. Tecvayli, in particular, combined meaningful late-line myeloma activity with an economic profile already capable of supporting a stronger reimbursement signal. Abelacimab also benefited from a favorable cost-effectiveness profile, although ongoing uncertainty remained around broader stroke-prevention evidence.

By contrast, several assets with strong or promising efficacy still sat in B++ or B+ because reimbursement-relevant evidence had not matured across the full framework. Retatrutide, CD388, Modeyso, Lumryz, and Ozureprubart illustrate the point from different therapeutic areas: the clinical story may be advancing, but HTA-aligned support remains incomplete when quality-of-life evidence is limited, comparator framing is still evolving, or formal economic analyses are not yet available.

Health-Related Quality of Life was a recurring constraint. Across much of the January cohort, validated patient-reported outcome evidence was absent, indirect, or insufficiently developed for strong utility interpretation. That matters because symptom improvement alone does not automatically convert into cost-utility strength.

Cost-Effectiveness was the largest rating limiter in the month. A substantial share of January assets either lacked published economic analyses or remained too early for credible ICER-based positioning. In reimbursement systems, that gap is not administrative. It directly affects price corridor sensitivity, negotiation leverage, and the probability of broad uptake.

What the Ratings Mean

A (Strong) indicates a strong probability of broad reimbursement under HTA scrutiny.

B++ (Marginal) indicates that reimbursement remains achievable but finely balanced, particularly in price-sensitive systems or where comparator and utility assumptions are exposed.

B+ (Very Weak) indicates a lower probability of reimbursement, with increased exposure to price pressure, restriction, delay, or rejection.

These are probability signals, not certainty statements.

Structural Implications for Stakeholders

For market access teams, the January cohort reinforces a basic discipline: early enthusiasm should not be confused with reimbursement readiness. For portfolio and diligence work, the more useful question is not whether an asset is clinically interesting, but whether it is becoming defensible under external scrutiny.

If a pricing or launch decision is later challenged, what independent benchmark was relied upon?

January’s pattern suggests that the main risk is not missing scientific innovation. It is overestimating how quickly that innovation converts into reimbursable value.

Methodological Integrity

All January actions reflect application of the same structured framework used across assets, ensuring comparability across time and portfolios. The assessments are calibrated to historical HTA logic, based on public evidence, and maintained through continuous surveillance.

January 2026 Ratings Issued

A: Abelacimab; Tecvayli
B++: Elevidys, Modeyso, Caplyta, Retatrutide, Lumryz
B+: CD388, Ozureprubart

MARA will continue to monitor material evidence events and adjust the reimbursement risk signal accordingly.